Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Share-based Compensation (2021 - 2023)

Historic Share-based Compensation for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to $7.5 million.

  • Cullinan Therapeutics' Share-based Compensation rose 7.99% to $7.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $30.4 million, marking a year-over-year increase of 887.43%. This contributed to the annual value of $37.8 million for FY2024, which is 2426.57% up from last year.
  • Cullinan Therapeutics' Share-based Compensation amounted to $7.5 million in Q4 2023, which was up 7.99% from $7.7 million recorded in Q3 2023.
  • Cullinan Therapeutics' Share-based Compensation's 5-year high stood at $12.1 million during Q4 2021, with a 5-year trough of $3.5 million in Q1 2021.
  • For the 3-year period, Cullinan Therapeutics' Share-based Compensation averaged around $6.9 million, with its median value being $7.4 million (2022).
  • Over the last 5 years, Cullinan Therapeutics' Share-based Compensation had its largest YoY gain of 10667.47% in 2022, and its largest YoY loss of 3813.92% in 2022.
  • Quarter analysis of 3 years shows Cullinan Therapeutics' Share-based Compensation stood at $12.1 million in 2021, then plummeted by 38.14% to $7.5 million in 2022, then rose by 0.08% to $7.5 million in 2023.
  • Its last three reported values are $7.5 million in Q4 2023, $7.7 million for Q3 2023, and $7.9 million during Q2 2023.